CN101961336B - 治疗哺乳动物包括人2型糖尿病的药物组合物 - Google Patents
治疗哺乳动物包括人2型糖尿病的药物组合物 Download PDFInfo
- Publication number
- CN101961336B CN101961336B CN2009101403973A CN200910140397A CN101961336B CN 101961336 B CN101961336 B CN 101961336B CN 2009101403973 A CN2009101403973 A CN 2009101403973A CN 200910140397 A CN200910140397 A CN 200910140397A CN 101961336 B CN101961336 B CN 101961336B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- pioglitazone
- rosiglitazone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101403973A CN101961336B (zh) | 2009-07-21 | 2009-07-21 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
PCT/CN2010/074309 WO2011009360A1 (fr) | 2009-07-21 | 2010-06-23 | Composition pharmaceutique pour le traitement du diabète de type 2 chez des mammifères comprenant les êtres humains |
HK11107352.4A HK1153143A1 (en) | 2009-07-21 | 2011-07-15 | Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101403973A CN101961336B (zh) | 2009-07-21 | 2009-07-21 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101961336A CN101961336A (zh) | 2011-02-02 |
CN101961336B true CN101961336B (zh) | 2012-05-30 |
Family
ID=43498754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101403973A Active CN101961336B (zh) | 2009-07-21 | 2009-07-21 | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101961336B (fr) |
HK (1) | HK1153143A1 (fr) |
WO (1) | WO2011009360A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108144065B (zh) * | 2016-12-06 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 一种dpp-4抑制剂的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101287495A (zh) * | 2005-06-10 | 2008-10-15 | 诺瓦提斯公司 | Dpp-iv抑制剂和格列酮的直接压片的制剂和制备方法 |
CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
-
2009
- 2009-07-21 CN CN2009101403973A patent/CN101961336B/zh active Active
-
2010
- 2010-06-23 WO PCT/CN2010/074309 patent/WO2011009360A1/fr active Application Filing
-
2011
- 2011-07-15 HK HK11107352.4A patent/HK1153143A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101287495A (zh) * | 2005-06-10 | 2008-10-15 | 诺瓦提斯公司 | Dpp-iv抑制剂和格列酮的直接压片的制剂和制备方法 |
CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2011009360A1 (fr) | 2011-01-27 |
HK1153143A1 (en) | 2012-03-23 |
CN101961336A (zh) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101365432B (zh) | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 | |
US20120059011A1 (en) | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone | |
CN106075451A (zh) | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 | |
CN106924208A (zh) | 一种复方达格列净二甲双胍缓释片及其制备方法 | |
JP2013508370A (ja) | ジペプチジルペプチダーゼ−4阻害剤とピオグリタゾンとの組み合わせの医薬組成物 | |
CN101919851B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN103893142A (zh) | 一种沙格列汀分散片及其制备方法 | |
JP2022544167A (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
CN101961336B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN101904840B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN103877043A (zh) | 一种磷酸西他列汀分散片及其制备方法 | |
EP2402342B1 (fr) | Composition pharmaceutique servant a traiter le diabete de type 2 | |
US8476272B2 (en) | Pharmaceutical composition for treatment of type 2 diabetes | |
CN109288836B (zh) | 一种复方硫酸双肼屈嗪制剂及其制备方法和应用 | |
CN106074553A (zh) | 含有西格列汀和二甲双胍的药物组合物 | |
TWI494313B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
TWI462925B (zh) | 治療2型糖尿病的藥物組合物 | |
TWI484955B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
TW202228701A (zh) | 包含格米列汀與達格列淨的口服組合製劑及其製備方法 | |
TW201219384A (en) | Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1153143 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1153143 Country of ref document: HK |